Related Experiment Video
Updated: Jul 4, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy
Sanna-Kaisa Herukka1, Corina Pennanen, Hilkka Soininen
1Department of Neurology, University of Kuopio, Kuopio, Finland. sanna-kaisa.herukka@uku.fi
Abstract:
Cerebrospinal fluid (CSF) biomarkers and medial temporal lobe (MTL) atrophy predict the progression of mild cognitive impairment (MCI) to Alzheimer's disease (AD). We investigated the association between the CSF biomarkers and MTL atrophy and the ability of these measures to predict AD in MCI patients in the same study population. The study included 21 MCI patients of whom eight progressed to AD during the study. CSF biomarkers were measured by using ELISA method and volumes of MTL structures were assessed by magnetic resonance imaging (MRI). Abeta42 levels were lower and tau and phospho-tau levels were higher in progressive subjects. The progressive subjects had lower volumes in all MRI measures. Tau and phospho-tau correlated inversely with hippocampal volumes and left entorhinal cortex volume in the whole study group. In the stable group, tau correlated with hippocampal volumes. Phospho-tau [corrected] had a negative correlation whereas Abeta42 [corrected] exhibited a positive correlation with left hippocampal volume in the progressive group. These results indicate that both measures may reflect the ongoing neurodegenerative process in the progressive MCI patients. However, the order of the changes in the CSF biomarkers and MTL atrophy remain unclear due to a small number of studied subjects and study design.
Insights
Cerebrospinal fluid biomarkers and medial temporal lobe atrophy predict Alzheimer's progression in mild cognitive impairment. Lower Abeta42 and higher tau/phospho-tau levels, along with reduced brain volumes, indicate neurodegeneration.
Area of Science:
- Neurology
- Biomarkers
- Neuroimaging
Background:
- Mild cognitive impairment (MCI) can progress to Alzheimer's disease (AD).
- Cerebrospinal fluid (CSF) biomarkers and medial temporal lobe (MTL) atrophy are known predictors of this progression.
- Investigating the interplay between these markers is crucial for early AD detection.
Purpose of the Study:
- To examine the association between CSF biomarkers and MTL atrophy.
- To assess the predictive capability of these measures for AD progression in MCI patients.
- To clarify the temporal relationship between biomarker changes and atrophy.
Main Methods:
- Studied 21 MCI patients, with 8 progressing to AD.
- Measured CSF biomarkers (Abeta42, tau, phospho-tau) using ELISA.
- Assessed MTL structure volumes via magnetic resonance imaging (MRI).
Main Results:
- Progressive subjects showed lower Abeta42 and higher tau/phospho-tau levels.
- Progressive subjects exhibited reduced volumes in all MRI measures.
- Tau and phospho-tau correlated inversely with hippocampal and entorhinal cortex volumes.
Conclusions:
- Both CSF biomarkers and MTL atrophy appear to reflect neurodegeneration in progressive MCI.
- The precise order of biomarker changes and atrophy requires further investigation due to study limitations.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Dementia l: Introduction
